Eniluracil (GW776C85) is an oral inhibitor of dihydropyrimidine dehydrogenase (DPD) that enables complete oral bioavailability of 5-fluorouracil (5-FU). It is used in research to study combination chemotherapy, predict pharmacokinetics, and investigate DPDs role in pyrimidine metabolism in both in vivo and in vitro models.